Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 8, 2007, Pages 2861-2866

  Weiner, Marc ^a,f   Burman, William ^b   Luo, Chi Cheng ^c   Peloquin, Charles A ^d   Engle, Melissa ^a   Goldberg, Stefan ^c   Agarwal, Vipin ^e   Vernon, Andrew ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b DENVER PUBLIC HEALTH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^e NorthEast Bioanalytical Laboratories   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ISONIAZID; MOXIFLOXACIN; PARACETAMOL; RIFAMPICIN;

ABNORMAL VISION; ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DIARRHEA; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TRANSPORT; ENZYME INDUCTION; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MULTIDRUG RESISTANCE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; TASTE; TUBERCULOSIS; VAGINITIS; XEROSTOMIA;

ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; QUINOLINES; RIFAMPIN; THERAPEUTIC EQUIVALENCY;

EID: 34547639372     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01621-06     Document Type: Article

References (20)

1. Burman, W. J., S. Goldberg, J. L. Johnson, G. Muzanye, M. Engle, A. W. Mosher, S. Choudhri, C. L. Daley, S. S. Munsiff, Z. Zhao, A. Vernon, R. E. Chaisson, and the Tuberculosis Trials Consortium. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:331-338.
2. Cancer Therapy Evaluation Program, National Cancer Institute. 30 April 1999, posting date. Common toxicity criteria, version 2.0. http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf.
3. de Lange, E., S. Marchand, D. van den Berg, I. van der Sandt, A. de Boer, A. Delon, S. Bouquet, and W. Couet. 2000. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur. J. Pharm. Sci. 12:85-93.
4. Dilger, K., B. Greiner, M. F. Fromm, U. Hofmann, H. K. Kroemer, and M. Eichelbaum. 1999. Consequences of rifampin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharmacogenetics 9:551-559.
5. Eichelbaum, M., M. Fromm, and M. Shwab. 2004. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26:180-185.
6. Gallicano, K. D., J. Sahai, V. K. Shukla, I. Seguin, A. Pakuts, D. Kwok, B. C. Foster, and D. W. Cameron. 1999. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br. J. Clin. Pharmacol. 48:168-179.
7. Hoffmeyer, S., O. Burk, O. von Richter, H. P. Arnold, J. Brockmoller, A. Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum, and U. Brinkmann. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-3478.
8. Johne, A., K. Kopke, T. Gerloff, I. Mai, S. Rietbrock, C. Meisel, S. Hoffmeyer, R. Kerb, M. F. Fromm, U. Brinkmann, M. Eichelbaum, J. Brockmoller, I. Cascorbi, and I. Roots. 2002. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72:584-594.
9. Kim, R. B. 2002. MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 12:425-427.
10. Mills, J. B., K. A. Rose, N. Sadagopan, J. Sahi, and S. M. de Morais. 2004. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J. Pharmacol. Exp. Ther. 309:303-330.
11. Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, R. J. O'Brien, A. N. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169:421-426.
12. Peloquin, C. A., R. Namdar, M. D. Singleton, and D. E. Nix. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18.
13. Putnam, W. S., J. M. Woo, Y. Huang, and L. Z. Benet. 2005. Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. J. Clin. Pharmacol. 45:411-421.
14. Sakaeda, T., T. Nakamura, and K. Okumura. 2004. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr. Top. Med. Chem. 4:1385-1398.
15. Shandil, R. K., R. Jayaram, P. Kaur, S. Gaonkar, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, and V. Balasubramanian. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582.
16. Song, P., S. Li, B. Meibohm, A. O. Gaber, M. R. Honaker, M. Kotb, and C. R. Yates. 2002. Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. AAPS PharmSci 4:E29.
17. Stass, H., and D. Kubitza. 1999. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J. Antimicrob. Chemother. 43(Suppl. B):83-90.
18. Venkatesan, K. 1992. Pharmacokinetic drug interactions with rifampicin. Clin. Pharmacokinet. 22:47-65.
19. Weiner, M., W. Burman, C. C. Luo, C. A. Peloquin, M. Engle, S. Goldberg, Z. Zhao, and A. Vernon for the Tuberculosis Trials Consortium. 2006. The effects of rifampin and human multidrug resistance gene polymorphism on serum concentrations of moxifloxacin. Proc. Am. Thorac. Soc. 3:A745.
20. Woodahl, E. L., and R. J. Ho. 2004. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr. Drug Metab. 5:11-19.